Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System (VIVID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04580160
Recruitment Status : Recruiting
First Posted : October 8, 2020
Last Update Posted : July 16, 2021
Sponsor:
Information provided by (Responsible Party):
Vesper Medical, Inc.

Brief Summary:
This is a prospective, multi-center, single-arm, non-blinded clinical trial designed to investigate the safety and efficacy of the Vesper DUO Venous Stent System as compared to a pre-defined performance goal (PG) established from published, peer reviewed scientific literature related to stenting of iliofemoral venous outflow obstructions.

Condition or disease Intervention/treatment Phase
May-Thurner Syndrome Deep Vein Thrombosis Chronic Venous Insufficiency Device: Duo Venous Stent System Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System
Actual Study Start Date : November 30, 2020
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Duo Venous Stent System Implantation Device: Duo Venous Stent System
Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with nonthrombotic (NT), acute thrombotic (AT) or chronic postthrombotic (CPT) disease pathogenesis will be selected for study participation.




Primary Outcome Measures :
  1. Safety - Freedom from major adverse events (MAEs) at 30 days [ Time Frame: 30 days ]

    Freedom from major adverse events (MAEs) at 30 days post index procedure, as adjudicated by the Clinical Events Committee (CEC) or Core Laboratory, including:

    • Device or procedure-related death
    • Device or procedure-related bleed at the target vessel and/or the target lesion or at the access site requiring surgical or endovascular intervention or blood transfusion of ≥2 units
    • Device or procedure-related venous injury occurring in the target vessel and/or the target lesion or at the access site requiring surgical or endovascular intervention
    • Major amputation of the target limb
    • Clinically significant pulmonary embolism (PE), confirmed by CT angiography
    • Stent embolization outside of the target vessel
    • Presence of new thrombus within the stented segment

  2. Efficacy - Primary patency of stented segment at 12 months [ Time Frame: 12 months ]

    Primary patency of stented segment at 12 months defined as freedom from:

    • Duplex Ultrasound (DUS) core laboratory adjudicated occlusion or stenosis >50% within the stented segment. If DUS shows >50% stenosis or occlusion, confirmation by diagnostic intravascular ultrasound (IVUS) is required.
    • CEC adjudicated clinically driven target lesion reintervention (CD-TLR) defined as endovascular or surgical procedure for new, recurrent, or worsening symptoms and core lab adjudicated >50% stenosis or occlusion within the stented segment confirmed by diagnostic IVUS



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males or non-pregnant, non-breastfeeding females ≥18 years of age at the time of consent
  2. Subject is able and willing to provide written informed consent prior to receiving any non-standard of care, protocol specific procedures
  3. Female subjects of childbearing potential must have a negative pregnancy test within 7 days prior to treatment and must use some form of contraception (abstinence is acceptable) throughout the time of clinical trial exit
  4. Willing and capable of complying with all required follow-up visits
  5. Estimated life expectancy ≥1 year
  6. Subject is ambulatory (use of assistive walking device such as a cane or walker is acceptable)
  7. Body mass index (BMI) <40
  8. Clinically significant symptomatic venous outflow obstruction in one iliofemoral venous segment (one limb) per subject, is indicated for venoplasty and stenting, and meets at least one of the following clinical indicators:

    1. CEAP score ≥3
    2. VCSS pain score ≥2
    3. Suspected deep vein thrombosis (DVT) with symptoms occurring prior to receiving a DUO Stent
  9. Subject is willing and able to comply with PI recommendation for compression therapy, if required
  10. Presence of unilateral, non-malignant venous obstruction of the common femoral vein (CFV), external iliac vein (EIV), common iliac vein (CIV), or any combination thereof, defined as a ≥50% reduction in target vessel lumen diameter and confirmed by venographic or IVUS imaging. The cranial point of the obstruction may extend to the iliac vein confluence of the inferior vena cava (IVC) and the caudal point may be 2mm above either the inflow of the deep femoral (or profunda) or the lesser trochanter, whichever is most cranial
  11. Obstructive lesion(s) able to be treated with continuous stent coverage
  12. Adequate inflow to the target lesion(s) involving at least a patent femoral or deep femoral vein and a landing zone in the CFV free from significant disease requiring treatment
  13. Reference vessel diameter is of adequate size to accommodate the appropriate size stent as measured by IVUS
  14. All vessels from insertion site through target vessel can accommodate a 9F or 10F sheath, depending on the stent size used
  15. Ability to cross interventional devices through target lesion(s)
  16. In DVT subjects, successful treatment of acute thrombus must have occurred prior to receiving any DUO Stents for an underlying obstructive lesion. Successful treatment of acute thrombus is defined as reestablishment of antegrade flow with ≤30% residual thrombus (confirmed by venogram or IVUS) and freedom from bleeding and symptomatic pulmonary embolism (confirmed by imaging). After successful treatment of thrombus is confirmed, eligible obstructive lesion(s) can be treated with a DUO Stent during the same procedure.
  17. All subjects must undergo a SARS-CoV-2 test and have a negative test result within 8 days of the index procedure. If a SARS-CoV-2 test is unavailable due to institution policy, a test shortage, or if there is a delay in test results, the subject must complete the COVID-19 questionnaire and must have answered NO to all questions to be eligible for enrollment. A SARS-CoV-2 test will not be required for enrollment if a subject has received a complete cycle of an authorized COVID-19 vaccine or has documented evidence of a positive COVID-19 antibody test and is asymptomatic and has no long-lasting effects (per PI discretion) from a prior COVID-19 infection.
  18. A measured temperature less than 99.5°F (37.5°C) on the day of the index procedure and no history of fever or feeling feverish within 14 days of the index procedure
  19. No prior history, within 60 days of the index procedure, of a SARS-CoV-2 positive test, or COVID-19 symptoms

Exclusion Criteria:

  1. Target limb symptoms caused by peripheral arterial disease
  2. Presence of unresolved significant pulmonary embolism prior to use of the DUO Venous Stent System confirmed by chest CT. If subject has documented history of significant pulmonary embolism within the last 6 months, a chest CT is required to confirm significant pulmonary embolism is not currently present.
  3. Presence of IVC obstruction or target venous obstruction that extends into the IVC
  4. Presence of acute DVT located outside target limb
  5. Contralateral venous occlusive disease of the CFV, EIV, and/or CIV, with planned treatment ≤390 days after the index procedure
  6. Uncontrolled or active coagulopathy or known, uncorrectable bleeding diathesis
  7. Coagulopathy causing INR >2 which is not amenable to medical treatment
  8. Platelet count <50,000 cells/mm3 or >1,000,000 cells/mm3 and/or White blood cell (WBC) <3,000 cells/mm3 or >12,500 cells/mm3
  9. Uncorrected hemoglobin of ≤9 g/dL
  10. Subject is on dialysis or has an estimated glomerular filtration rate (eGFR) <30 mL/min. In subjects with diabetes mellitus, eGFR <45 mL/min.
  11. History of Heparin Induced Thrombocytopenia
  12. Presence of known aggressive clotting disorders such as Lupus Anticoagulant Disorder, Antiphospholipid antibody syndrome, homozygous gene Factor V Leiden or Prothrombin gene abnormalities, Protein C and S deficiency or Antithrombin deficiency
  13. Known hypersensitivity or contraindication to antiplatelet therapy or anticoagulation, nickel, or titanium
  14. Contrast agent allergy that cannot be managed adequately with pre-medication
  15. Intended concurrent adjuvant procedure (except for venoplasty) such as creation of temporary arteriovenous fistula, femoral endovenectomy or saphenous vein ablation and/or saphenous vein stripping during the index procedure
  16. Subjects who have had any prior surgical or endovascular procedures to the target vessel. Note that subjects who have had successful catheter-directed or mechanical thrombolysis in the target vessel for DVT at least 90 days prior to the index procedure may be included
  17. Planned surgical or interventional procedures of the target limb (except thrombolysis and/or thrombectomy in preparation for the procedure or vena cava filter placement prior to stent implantation in subjects at high risk for pulmonary embolism) within 30 days prior to or 30 days after the index procedure
  18. Planned surgical or interventional procedures for other medical conditions (i.e., not associated with the target limb) 30 days prior to or 30 days after the index procedure
  19. Previous venous stenting of the target limb, the IVC, or contralateral limb if stents extend into the IVC
  20. Iliofemoral venous segment unsuitable for treatment with available sizes of DUO Stent implants
  21. Lesions with intended treatment lengths extending into the IVC
  22. No safe landing zone at or above the profunda femoral confluence
  23. Participating in another investigational study in which the subject has not completed the primary endpoint(s)
  24. Has other comorbidities that, in the opinion of the Investigator, would preclude them from receiving this treatment and/or participating in study-required follow-up assessments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04580160


Contacts
Layout table for location contacts
Contact: Joseph C Griffin 14848926340 jgriffin@vespermedical.com

Locations
Show Show 28 study locations
Sponsors and Collaborators
Vesper Medical, Inc.
Layout table for additonal information
Responsible Party: Vesper Medical, Inc.
ClinicalTrials.gov Identifier: NCT04580160    
Other Study ID Numbers: V-CA-0001
First Posted: October 8, 2020    Key Record Dates
Last Update Posted: July 16, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombosis
Venous Thrombosis
Venous Insufficiency
May-Thurner Syndrome
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Vascular Malformations
Cardiovascular Abnormalities
Peripheral Vascular Diseases
Congenital Abnormalities